Tags

Type your tag names separated by a space and hit enter

Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.

Abstract

BACKGROUND

In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using an observational study (cycEVA) conducted in the frame of the Spanish Influenza Sentinel Surveillance System. We aimed to measure the effectiveness of the seasonal trivalent vaccine in preventing influenza like illness (ILI) laboratory-confirmed influenza infection at the end of the season 2010-11.

METHODS

We conducted a test-negative case-control study between weeks 50/2010 and 12/2011. Cases were ILI laboratory-confirmed influenza infection and controls were those testing negative. Sentinel physicians collected data on demographic and clinical characteristics, vaccination status, and on covariates related to confounding factors associating with influenza VE. We calculated adjusted odds ratios (OR), using logistic regression and computed influenza VE as (1-OR) × 100.

RESULTS

The adjusted influenza VE against A(H1N1)pdm09 infection was 46% (95% confidence interval (95%CI): 0; 72). In A(H1N1)pdm09 infected patients who had received both 2010-11 trivalent influenza seasonal and 2009 monovalent pandemic vaccines, influenza VE was 74% (95%CI: 13; 93). The adjusted influenza VE against B infection was 23% (95%CI: -180; 79).

CONCLUSION

The trivalent influenza vaccine 2010-11 showed a moderate VE for preventing ILI laboratory confirmed influenza infections. Influenza VE estimates were higher in patients who had received both 2010-11 seasonal trivalent and 2009 monovalent pandemic vaccines.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid, Spain. sjimenezj@isciii.es

    , , , , , , ,

    Source

    Vaccine 30:24 2012 May 21 pg 3595-602

    MeSH

    Adolescent
    Adult
    Aged
    Aged, 80 and over
    Case-Control Studies
    Child
    Child, Preschool
    Female
    Humans
    Infant
    Infant, Newborn
    Influenza Vaccines
    Influenza, Human
    Male
    Middle Aged
    Spain
    Young Adult

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22472792

    Citation

    Jiménez-Jorge, S, et al. "Effectiveness of the 2010-11 Seasonal Trivalent Influenza Vaccine in Spain: cycEVA Study." Vaccine, vol. 30, no. 24, 2012, pp. 3595-602.
    Jiménez-Jorge S, Savulescu C, Pozo F, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine. 2012;30(24):3595-602.
    Jiménez-Jorge, S., Savulescu, C., Pozo, F., de Mateo, S., Casas, I., Ledesma, J., & Larrauri, A. (2012). Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine, 30(24), pp. 3595-602. doi:10.1016/j.vaccine.2012.03.048.
    Jiménez-Jorge S, et al. Effectiveness of the 2010-11 Seasonal Trivalent Influenza Vaccine in Spain: cycEVA Study. Vaccine. 2012 May 21;30(24):3595-602. PubMed PMID: 22472792.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. AU - Jiménez-Jorge,S, AU - Savulescu,C, AU - Pozo,F, AU - de Mateo,S, AU - Casas,I, AU - Ledesma,J, AU - Larrauri,A, AU - ,, AU - ,, Y1 - 2012/03/31/ PY - 2011/12/23/received PY - 2012/03/16/revised PY - 2012/03/19/accepted PY - 2012/4/5/entrez PY - 2012/4/5/pubmed PY - 2012/9/13/medline SP - 3595 EP - 602 JF - Vaccine JO - Vaccine VL - 30 IS - 24 N2 - BACKGROUND: In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using an observational study (cycEVA) conducted in the frame of the Spanish Influenza Sentinel Surveillance System. We aimed to measure the effectiveness of the seasonal trivalent vaccine in preventing influenza like illness (ILI) laboratory-confirmed influenza infection at the end of the season 2010-11. METHODS: We conducted a test-negative case-control study between weeks 50/2010 and 12/2011. Cases were ILI laboratory-confirmed influenza infection and controls were those testing negative. Sentinel physicians collected data on demographic and clinical characteristics, vaccination status, and on covariates related to confounding factors associating with influenza VE. We calculated adjusted odds ratios (OR), using logistic regression and computed influenza VE as (1-OR) × 100. RESULTS: The adjusted influenza VE against A(H1N1)pdm09 infection was 46% (95% confidence interval (95%CI): 0; 72). In A(H1N1)pdm09 infected patients who had received both 2010-11 trivalent influenza seasonal and 2009 monovalent pandemic vaccines, influenza VE was 74% (95%CI: 13; 93). The adjusted influenza VE against B infection was 23% (95%CI: -180; 79). CONCLUSION: The trivalent influenza vaccine 2010-11 showed a moderate VE for preventing ILI laboratory confirmed influenza infections. Influenza VE estimates were higher in patients who had received both 2010-11 seasonal trivalent and 2009 monovalent pandemic vaccines. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22472792/Effectiveness_of_the_2010_11_seasonal_trivalent_influenza_vaccine_in_Spain:_cycEVA_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(12)00440-9 DB - PRIME DP - Unbound Medicine ER -